TDOC PE Ratio & Valuation,Is TDOC Overvalued

TDOC Relative Valuation

TDOC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TDOC is overvalued; if below, it's undervalued.

Historical Valuation

Teladoc Health Inc (TDOC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -31.12. The fair price of Teladoc Health Inc (TDOC) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：7.34

Fair

-8.01

5.67

EV/EBITDA

Teladoc Health Inc. (TDOC) has a current EV/EBITDA of 5.67. The 5-year average EV/EBITDA is 30.27. The thresholds are as follows: Strongly Undervalued below -40.21, Undervalued between -40.21 and -4.97, Fairly Valued between 65.51 and -4.97, Overvalued between 65.51 and 100.75, and Strongly Overvalued above 100.75. The current Forward EV/EBITDA of 5.67 falls within the Historic Trend Line -Fairly Valued range.

-10.34

EV/EBIT

Teladoc Health Inc. (TDOC) has a current EV/EBIT of -10.34. The 5-year average EV/EBIT is -48.32. The thresholds are as follows: Strongly Undervalued below -439.41, Undervalued between -439.41 and -243.87, Fairly Valued between 147.22 and -243.87, Overvalued between 147.22 and 342.76, and Strongly Overvalued above 342.76. The current Forward EV/EBIT of -10.34 falls within the Historic Trend Line -Fairly Valued range.

0.53

Teladoc Health Inc. (TDOC) has a current PS of 0.53. The 5-year average PS is 3.60. The thresholds are as follows: Strongly Undervalued below -5.71, Undervalued between -5.71 and -1.05, Fairly Valued between 8.25 and -1.05, Overvalued between 8.25 and 12.90, and Strongly Overvalued above 12.90. The current Forward PS of 0.53 falls within the Historic Trend Line -Fairly Valued range.

4.42

P/OCF

Teladoc Health Inc. (TDOC) has a current P/OCF of 4.42. The 5-year average P/OCF is 38.09. The thresholds are as follows: Strongly Undervalued below -65.62, Undervalued between -65.62 and -13.77, Fairly Valued between 89.94 and -13.77, Overvalued between 89.94 and 141.80, and Strongly Overvalued above 141.80. The current Forward P/OCF of 4.42 falls within the Historic Trend Line -Fairly Valued range.

6.65

P/FCF

Teladoc Health Inc. (TDOC) has a current P/FCF of 6.65. The 5-year average P/FCF is 61.86. The thresholds are as follows: Strongly Undervalued below -119.69, Undervalued between -119.69 and -28.91, Fairly Valued between 152.64 and -28.91, Overvalued between 152.64 and 243.42, and Strongly Overvalued above 243.42. The current Forward P/FCF of 6.65 falls within the Historic Trend Line -Fairly Valued range.

Teladoc Health Inc (TDOC) has a current Price-to-Book (P/B) ratio of 0.94. Compared to its 3-year average P/B ratio of 1.24 , the current P/B ratio is approximately -24.76% higher. Relative to its 5-year average P/B ratio of 1.28, the current P/B ratio is about -27.11% higher. Teladoc Health Inc (TDOC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 14.53%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 9.21% , the current FCF yield is about -100.00% lower.

0.94

P/B

Median3y

1.24

Median5y

1.28

20.90

FCF Yield

Median3y

14.53

Median5y

9.21

Competitors Valuation Multiple

The average P/S ratio for TDOC's competitors is , providing a benchmark for relative valuation. Teladoc Health Inc Corp (TDOC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -2.20%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of TDOC decreased by 19.25% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -5.20 to -7.90.

The secondary factor is the Revenue Growth, contributed -2.20%to the performance.

Overall, the performance of TDOC in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-2.20%

640.51M → 626.44M

Revenue Growth

51.92%

-5.20 → -7.90

Margin Expansion

-68.97%

-18.53 → -5.75

P/E Change

-19.25%

9.09 → 7.34

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Teladoc Health Inc (TDOC) currently overvalued or undervalued?

What is Teladoc Health Inc (TDOC) fair value?

TDOC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Teladoc Health Inc (TDOC) is between NaN to NaN according to relative valuation methord.

How does TDOC's valuation metrics compare to the industry average?

What is the current P/B ratio for Teladoc Health Inc (TDOC) as of Dec 16 2025?

As of Dec 16 2025, Teladoc Health Inc (TDOC) has a P/B ratio of 0.94. This indicates that the market values TDOC at 0.94 times its book value.

What is the current FCF Yield for Teladoc Health Inc (TDOC) as of Dec 16 2025?

As of Dec 16 2025, Teladoc Health Inc (TDOC) has a FCF Yield of 0.00%. This means that for every dollar of Teladoc Health Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Teladoc Health Inc (TDOC) as of Dec 16 2025?

As of Dec 16 2025, Teladoc Health Inc (TDOC) has a Forward P/E ratio of -8.01. This means the market is willing to pay $-8.01 for every dollar of Teladoc Health Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Teladoc Health Inc (TDOC) as of Dec 16 2025?

As of Dec 16 2025, Teladoc Health Inc (TDOC) has a Forward P/S ratio of 0.00. This means the market is valuing TDOC at $0.00 for every dollar of expected revenue over the next 12 months.

TDOC Valuation